Mir Ali, MD
Infectious Disease · Corpus Christi, TXNPI 1053676858
Payments from drug & device makers
Across 37 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$140
- Viiv Healthcare Company$132
- Jazz Pharmaceuticals Inc.$94
- EMD Serono, Inc.$88
- AbbVie$81
- Biomerieux Inc$78
- plus $277 from 8 others
What the payments were for
- Consulting fees$789%
- Food & beverage$81291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $140 |
| Viiv Healthcare Company | 7 | $132 |
| Jazz Pharmaceuticals Inc. | 6 | $94 |
| EMD Serono, Inc. | 1 | $88 |
| AbbVie(2 entities) | 5 | $81 |
| Biomerieux Inc | 1 | $78 |
| Merck | 4 | $67 |
| Johnson & Johnson | 3 | $50 |
| Boehringer Ingelheim | 2 | $35 |
| W. L. Gore & Associates, Inc. | 1 | $31 |
| Harmony Biosciences LLC | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$890 in reported general payments places this provider in the 50th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefepime Hcl | 35 | $12,736 |
| Vancomycin Hcl | 42 | $12,484 |
| Meropenem | 29 | $5,222 |
| Cefazolin Sodium | 22 | $1,040 |
| Atorvastatin Calcium | 25 | $95 |
| Hydralazine Hcl | 15 | $82 |
| Furosemide | 21 | $81 |
| ClopidogrelClopidogrel Bisulfate | 11 | $72 |
| Pantoprazole Sodium | 20 | $67 |
| Prednisone | 12 | $39 |
| Amlodipine Besylate | 13 | $26 |
| Lisinopril | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Corpus Christi
- Srikanth RamachandruniCorpus Christi$115K
- Gene VoskuhlSherman$69.5M
- Mezgebe BerheDallas$11M
- Eleftherios MylonakisHouston$6.4M
- Mamta JainDallas$3.7M
- Cheryl McDonaldFort Worth$3.1M
- Ogechika AlozieEl Paso$2.5M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.